In Brief: FDA reform
This article was originally published in The Rose Sheet
Executive Summary
FDA reform: House FDA reform leadership has conceded that FDA reform will not move this year. House Commerce Committee/Health Subcommittee mark-up of the three-part bill was postponed once again in August until Congress resumed its session in September following the summer recess ("The Rose Sheet" Aug. 5, p. 11.) The measure has been tagged as a priority for next year. Commerce Committee Counsel John Cohrssen told a Food & Drug Law Institute meeting Sept. 5 that work would still continue through September on the measure. Senate efforts on a substitute amendment for FDA reform legislation (S 1477) continue as well; a memo sent the week of Sept. 2 to Senate Labor & Human Resources staff indicates that Sen. Kassebaum (R-Kan.) still hopes to bring FDA reform to the floor...